IL266750A - Methods of enhancing immune response with everolimus, dactolisib or both - Google Patents

Methods of enhancing immune response with everolimus, dactolisib or both

Info

Publication number: IL266750A
Authority: IL; Israel
Prior art keywords: dactolisib; everolimus; methods; immune response; enhancing immune
Prior art date: 2016-11-23

Application number

IL266750A

Other languages

English (en)

Hebrew (he)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-23

Filing date

2019-05-20

Publication date

2019-07-31

2019-05-20 Application filed by Novartis Ag filed Critical Novartis Ag

2019-07-31 Publication of IL266750A publication Critical patent/IL266750A/en

Links

HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 title 1
JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 title 1
229950006418 dactolisib Drugs 0.000 title 1
230000002708 enhancing effect Effects 0.000 title 1
229960005167 everolimus Drugs 0.000 title 1
230000028993 immune response Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL266750A 2016-11-23 2019-05-20 Methods of enhancing immune response with everolimus, dactolisib or both IL266750A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201662425766P	2016-11-23	2016-11-23
US201762476160P	2017-03-24	2017-03-24
US201762576511P	2017-10-24	2017-10-24
PCT/IB2017/001579 WO2018096402A1 (en)	2016-11-23	2017-11-22	Methods of enhancing immune response with everolimus, dactolisib or both

Publications (1)

Publication Number	Publication Date
IL266750A true IL266750A (en)	2019-07-31

Family

ID=60957348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL266750A IL266750A (en)	2016-11-23	2019-05-20	Methods of enhancing immune response with everolimus, dactolisib or both

Country Status (12)

Country	Link
US (3)	US10441584B2 (2)
EP (1)	EP3544608A1 (2)
JP (1)	JP2020500930A (2)
KR (1)	KR20190089005A (2)
CN (1)	CN110114070A (2)
AU (1)	AU2017363970A1 (2)
BR (1)	BR112019010470A2 (2)
CA (1)	CA3044355A1 (2)
IL (1)	IL266750A (2)
MX (1)	MX2019006090A (2)
TW (1)	TW201825090A (2)
WO (1)	WO2018096402A1 (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11083725B2 (en)	2014-10-24	2021-08-10	St. Jude Children's Research Hospital	Coordinated metabolic reprogramming in response to productive viral infections
CN110114070A (zh)	2016-11-23	2019-08-09	诺华公司	使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
WO2020223154A1 (en) *	2019-05-01	2020-11-05	resTORbio, Inc.	Methods of enhancing immune response

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1028606A (en)		1912-06-04	Victor Talking Machine Co	Sound-box for talking-machines.
US1000480A (en)	1909-05-19	1911-08-15	J G Brill Co	Car-truck.
US1044158A (en)	1911-01-27	1912-11-12	Allen H Fetzer	Trolley-wheel.
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US5472712A (en)	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en)	1991-12-24	1997-10-28	Euro-Celtique, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
CA2175215C (en)	1993-11-19	2008-06-03	Yat Sun Or	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
SK78196A3 (en)	1993-12-17	1997-02-05	Sandoz Ag	Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5741677A (en)	1995-06-07	1998-04-21	Geron Corporation	Methods for measuring telomere length
US5985890A (en)	1995-06-09	1999-11-16	Novartis Ag	Rapamycin derivatives
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
AU735648B2 (en)	1996-07-12	2001-07-12	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
CA2230748C (en)	1997-03-14	2010-08-03	American Home Products Corporation	Rapamycin formulations for oral administration
US6015815A (en)	1997-09-26	2000-01-18	Abbott Laboratories	Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
ME00189B (me)	1998-03-26	2011-02-10	Astellas Pharma Inc	Preparati sa neprekidnim oslobađanjem
ATE264863T1 (de)	1999-08-24	2004-05-15	Ariad Gene Therapeutics Inc	28-epirapaloge
GB0008785D0 (en)	2000-04-10	2000-05-31	Novartis Ag	Organic compounds
GB0123400D0 (en)	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
PT1478648E (pt)	2002-02-01	2014-07-15	Ariad Pharma Inc	Compostos contendo fósforo e suas utilizações
US20030203027A1 (en)	2002-04-26	2003-10-30	Ethicon, Inc.	Coating technique for deposition of drug substance on a substrate
US7075204B2 (en)	2003-08-06	2006-07-11	Honeywell International, Inc.	Threaded inner sleeve for generator magnet
AR045957A1 (es)	2003-10-03	2005-11-16	Novartis Ag	Composicion farmaceutica y combinacion
US7220755B2 (en)	2003-11-12	2007-05-22	Biosensors International Group, Ltd.	42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
GB0419355D0 (en)	2004-08-31	2004-09-29	Novartis Ag	Organic compounds
US8758816B2 (en)	2004-11-24	2014-06-24	Meda Pharmaceuticals Inc.	Compositions comprising azelastine and methods of use thereof
DK1848431T3 (en)	2005-02-09	2016-04-18	Santen Pharmaceutical Co Ltd	LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
BRPI0608573A2 (pt)	2005-03-08	2017-07-25	Lifecycle Pharma As	Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
ES2563288T3 (es)	2006-03-23	2016-03-14	Santen Pharmaceutical Co., Ltd	Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US20100266590A1 (en)	2006-08-02	2010-10-21	Demetri George D	Combination therapy
EP1902708A1 (de)	2006-09-25	2008-03-26	Losan Pharma GmbH	Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung
KR20140091718A (ko)	2006-11-20	2014-07-22	노파르티스 아게	2-메틸-2-［4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조［4,5-ｃ］퀴놀린-1-일)-페닐］-프로피오니트릴의 염 및 결정 형태
AU2008218806B2 (en)	2007-02-20	2011-12-01	Novartis Ag	Imidazoquinolines as dual lipid kinase and mTOR inhibitors
PL2182948T3 (pl)	2007-07-24	2013-07-31	Novartis Ag	Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
US20090082387A1 (en)	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched nvp-bez234
US20090088373A1 (en)	2007-09-28	2009-04-02	Gallo Richard L	Use of compositions to enhance innate immune response
JP2011513391A (ja)	2008-03-05	2011-04-28	パナセアバイオテックリミテッド	ミコフェノラートを含有する徐放性医薬組成物およびその方法
KR20100126553A (ko)	2008-03-26	2010-12-01	노파르티스 아게	Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체
CA2733203A1 (en)	2008-08-05	2010-02-11	Emory University	Use of mtor inhibitors to enhance t cell immune responses
EP2331566B1 (en)	2008-08-26	2015-10-07	City of Hope	Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010049481A1 (en)	2008-10-31	2010-05-06	Novartis Ag	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US8323649B2 (en)	2008-11-25	2012-12-04	Alderbio Holdings Llc	Antibodies to IL-6 and use thereof
US9452227B2 (en)	2008-11-25	2016-09-27	Alderbio Holdings Llc	Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
EP2375897A4 (en)	2009-01-14	2013-05-15	Health Research Inc	METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS
US20100233733A1 (en)	2009-02-10	2010-09-16	Nodality, Inc., A Delaware Corporation	Multiple mechanisms for modulation of the pi3 kinase pathway
CA2757979A1 (en)	2009-04-09	2010-10-14	Alkermes Pharma Ireland Limited	Controlled-release clozapine compositions
BRPI1010655A2 (pt)	2009-04-10	2019-09-03	Qi Haiyan	novos agentes antienvelhecimento e métodos para identificá-los
CN101862297B (zh)	2009-04-14	2012-07-25	上海医药工业研究院	一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法
US20120114637A1 (en)	2009-05-04	2012-05-10	Santen Pharmaceutical Co., Ltd.	Mtor pathway inhibitors for treating ocular disorders
JP2013504325A (ja)	2009-09-09	2013-02-07	アビラセラピューティクス，インコーポレイテッド	Ｐｉ３キナーゼインヒビターおよびその使用
CN102199152A (zh)	2010-03-25	2011-09-28	高大新	杂环咪唑类磷脂激酶抑制剂
US20130296316A1 (en)	2010-07-09	2013-11-07	Michael P. Pollastri	Antiparasitic Agents Based On mTOR Inhibitors
AR083267A1 (es)	2010-10-04	2013-02-13	Novartis Ag	Combinaciones farmaceuticas
WO2012075253A2 (en)	2010-12-03	2012-06-07	Novartis Ag	Pharmaceutical compositions
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
EP2667874A4 (en)	2011-01-27	2014-07-30	Univ Princeton	MTOR KINASE HEMMER AS ANTIVIRUS AGENT
CN103391780B (zh) *	2011-02-16	2015-08-19	诺瓦提斯公司	用于治疗神经变性疾病的治疗剂的组合物
CN102138903B (zh)	2011-03-17	2012-12-12	苏州特瑞药业有限公司	一种依维莫司固体口服药物组合物
EP2741747A1 (en)	2011-08-10	2014-06-18	Novartis Pharma AG	JAK P13K/mTOR COMBINATION THERAPY
MX2014003873A (es)	2011-09-30	2014-05-28	Dana Farber Cancer Inst Inc	Metodo para tratar el carcinoma mucoepidermoide.
ES2663744T3 (es)	2011-10-06	2018-04-16	Novartis Ag	Composiciones farmacéuticas que comprenden 40-O-(2-hidroxi)etil-rapamicina
EP2638896A1 (en)	2012-03-14	2013-09-18	Bioneer A/S	Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
RU2766608C2 (ru)	2012-04-11	2022-03-15	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
RU2014154009A (ru)	2012-06-06	2016-08-10	Новартис Аг	Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
US10799473B2 (en)	2013-03-04	2020-10-13	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence
TW201503912A (zh)	2013-03-19	2015-02-01	Novartis Ag	包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014191128A1 (en)	2013-05-29	2014-12-04	Cellectis	Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
KR101582264B1 (ko)	2013-06-27	2016-01-04	삼성전자 주식회사	유기 박막용 조성물, 유기 박막 및 상기 유기 박막을 포함하는 전자 소자
US9033062B2 (en) *	2013-07-11	2015-05-19	Caterpillar Inc.	Control system for a machine
AU2014348657A1 (en)	2013-11-13	2016-05-19	Novartis Ag	mTOR inhibitors for enhancing the immune response
SI3151672T1 (sl)	2014-06-06	2021-03-31	Bluebird Bio, Inc.	Izboljšani T-celični sestavki
SG10201913782UA (en)	2014-07-21	2020-03-30	Novartis Ag	Treatment of cancer using a cll-1 chimeric antigen receptor
US20170274014A1 (en)	2014-07-21	2017-09-28	Jennifer Brogdon	Combinations of low, immune enhancing, doses of mtor inhibitors and cars
TWI719942B (zh)	2014-07-21	2021-03-01	瑞士商諾華公司	使用ｃｄ３３嵌合抗原受體治療癌症
BR112017001183A2 (pt)	2014-07-21	2017-11-28	Novartis Ag	tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
JP2017528433A (ja)	2014-07-21	2017-09-28	ノバルティスアーゲー	低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
MX2017002205A (es)	2014-08-19	2017-08-21	Novartis Ag	Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
US11083725B2 (en) *	2014-10-24	2021-08-10	St. Jude Children's Research Hospital	Coordinated metabolic reprogramming in response to productive viral infections
WO2016079332A1 (en)	2014-11-21	2016-05-26	Technical University Of Denmark	Gel formulations for improving immunotherapy
CA2986359A1 (en)	2015-05-20	2016-11-24	Novartis Ag	Pharmaceutical combination of everolimus with dactolisib
CN110114070A (zh)	2016-11-23	2019-08-09	诺华公司	使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法

2017
- 2017-11-22 CN CN201780080148.2A patent/CN110114070A/zh active Pending
- 2017-11-22 EP EP17829013.6A patent/EP3544608A1/en not_active Withdrawn
- 2017-11-22 CA CA3044355A patent/CA3044355A1/en not_active Abandoned
- 2017-11-22 TW TW106140519A patent/TW201825090A/zh unknown
- 2017-11-22 MX MX2019006090A patent/MX2019006090A/es unknown
- 2017-11-22 WO PCT/IB2017/001579 patent/WO2018096402A1/en not_active Ceased
- 2017-11-22 US US15/821,229 patent/US10441584B2/en active Active
- 2017-11-22 BR BR112019010470A patent/BR112019010470A2/pt not_active Application Discontinuation
- 2017-11-22 JP JP2019547795A patent/JP2020500930A/ja active Pending
- 2017-11-22 KR KR1020197017560A patent/KR20190089005A/ko not_active Withdrawn
- 2017-11-22 AU AU2017363970A patent/AU2017363970A1/en not_active Abandoned
2019
- 2019-05-20 IL IL266750A patent/IL266750A/en unknown
- 2019-10-03 US US16/592,248 patent/US11045463B2/en active Active
- 2019-10-03 US US16/592,293 patent/US10993940B2/en active Active

Also Published As

Publication number	Publication date
US20180161319A1 (en)	2018-06-14
US20200054624A1 (en)	2020-02-20
CN110114070A (zh)	2019-08-09
EP3544608A1 (en)	2019-10-02
US20200061051A1 (en)	2020-02-27
TW201825090A (zh)	2018-07-16
US10441584B2 (en)	2019-10-15
US11045463B2 (en)	2021-06-29
JP2020500930A (ja)	2020-01-16
WO2018096402A1 (en)	2018-05-31
KR20190089005A (ko)	2019-07-29
AU2017363970A1 (en)	2019-06-20
MX2019006090A (es)	2019-08-21
US10993940B2 (en)	2021-05-04
BR112019010470A2 (pt)	2019-09-10
CA3044355A1 (en)	2018-05-31

Publication	Publication Date	Title
GB2530726B (en)	2016-11-02	Distributed single sign-on
EP3175592A4 (en)	2018-01-17	Orthogonal differential vector signaling codes with embedded clock
GB201615128D0 (en)	2016-10-19	Methods
IL247614A0 (en)	2016-11-30	Methods and preparations for changing the immune response
GB201610162D0 (en)	2016-07-27	Methods
PL3207273T3 (pl)	2020-12-14	Zespół amortyzatora
GB201709075D0 (en)	2017-07-19	Methods
HUE049290T2 (hu)	2020-09-28	Leválasztó
GB201621728D0 (en)	2017-02-01	Methods
GB201622086D0 (en)	2017-02-08	Biocontrol organism
GB201511969D0 (en)	2015-08-19	Biosensor
GB201615343D0 (en)	2016-10-26	Methods
IL266750A (en)	2019-07-31	Methods of enhancing immune response with everolimus, dactolisib or both
GB201620668D0 (en)	2017-01-18	Demodulation
GB201621386D0 (en)	2017-02-01	Methods
EP3105458A4 (en)	2017-10-25	Garment weight clip
GB2567755C (en)	2022-01-19	Cooker
PT3335725T (pt)	2024-05-08	Epítopos pds5a como indutores de imunidade
IL264299A (en)	2019-02-28	safe box
GB201501523D0 (en)	2015-03-18	Differential immune response modulation
GB2549811B (en)	2018-12-26	Stove
GB201601868D0 (en)	2016-03-16	Methods
GB2567330B (en)	2022-03-09	Cooker
GB201619945D0 (en)	2017-01-11	Methods
HK40014245A (en)	2020-08-14	Methods of enhancing immune response with everolimus, dactolisib or both